On Thursday, Shares of Sunedison Inc (NYSE:SUNE), gained 0.14% to $7.19.
Sunedison declared the completion of three solar canopy systems for the City of Fremont, Calif. The systems are predictable to generate 1.2 megawatts (MW) DC of clean, reliable electricity for the city.
The solar canopy systems are mounted on canopy structures over parking lots at the city’s Irvington Community Center, the Aqua Adventure Water Park, and the Robert Wasserman Fremont Police Center. The solar systems are predictable to generate enough energy to power almost 150 homes each year and avoid the emission of more than 500 tons of carbon dioxide annually, equivalent to the amount of carbon sequestered by about 425 acres of forest.
The City of Fremont signed 20-year power purchase agreements with SunEdison as part of the Regional Renewable Energy Procurement Program (R-REP) led by Alameda County. It is projecting that the solar energy will save taxpayers more than $2.6 million dollars over the life of the agreement, and will result in a more than 5 percent reduction in city emissions following the completion of a fourth canopy system early next year.
SunEdison, Inc. (SunEdison) is a developer and seller of photovoltaic energy solutions, an owner and operator of clean power generation assets, and a developer and manufacturer of silicon wafers.
Shares of Hilton Worldwide Holdings Inc (NYSE:HLT), inclined 2.35% to $23.48, during its last trading session.
Hilton Worldwide Holdings declared a new industry-leading GED Assistance benefit that will give thousands of eligible Team Members the opportunity to earn their high school equivalency diploma. The new program marks the largest, most comprehensive high school diploma assistance benefit offered by a major hospitality company in the United States.
The GED Assistance program is available to all full-time U.S. Team Members at owned and managed hotels and corporate offices with six months of service or greater. The new benefit will provide one-on-one advising and test preparation support. It will be free of charge for Team Members, and will also cover the cost of taking the GED tests.
“Our Team Members are at the heart of our success and we are committed to ensuring Hilton is a place where they can grow both personally and professionally,” said Christopher J. Nassetta, President & CEO, Hilton Worldwide. “Earning a high school diploma is a major accomplishment in people’s lives, and this new benefit will assist many of our Team Members experience the joy of reaching that milestone and unlocking new career opportunities.”
Hilton is working with the Council for Adult and Experiential Learning (CAEL) on this program. CAEL is a leading national nonprofit whose aim is to provide adults with easier access to education and learning opportunities.
Hilton Worldwide Holdings Inc. is a hospitality company. The Company comprises of about 4,322 hotels, resorts and timeshare properties comprising of 715,062 rooms in 94 countries and territories. The Company operates through three segments: administration and franchise, ownership and timeshare.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), inclined 1.40% to $60.03, during its last trading session.
Bristol-Myers Squibb Company declared that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Today’s declaration marks the first and only FDA approval of a Regimen of two Immuno-Oncology agents in cancer. This indication is approved under accelerated approval based on tumor response rate and durability of response.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
The approval is based on data from the pivotal study, CheckMate -069, which was the first to report outcomes of the Opdivo + Yervoy Regimen in formerly untreated patients with unresectable or metastatic melanoma. Results from the trial demonstrated a statistically noteworthy(p<0.001) improvement in confirmed objective response rate – the study’s primary endpoint – in patients with BRAF wild-type melanoma treated with the Opdivo + Yervoy Regimen [60% (95% CI: 48-71; p<0.001)] contrast to those treated with Yervoy monotherapy [11% (95% CI: 3-25)]. Complete responses were seen in 17% of patients. Partial responses were seen in 43% of the Regimen group and 11% of the Yervoy monotherapy group. The Opdivo + Yervoy Regimen demonstrated a 60% reduction in the risk of progression vs. Yervoy alone (HR=0.40; 95% CI: 0.22-0.71; p<0.002). Median PFS was 8.9 months with the Regimen (95% CI: 7.0, NA) and 4.7 months with Yervoy alone (95% CI: 2.8-5.3).1 This trial provides clinical rationale for targeting the immune system with two Immuno-Oncology agents in metastatic melanoma.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries.
Finally, AbbVie Inc (NYSE:ABBV), ended its last trade with 1.30% gain, and closed at $55.12.
AbbVie declared that 34 abstracts from its chronic hepatitis C clinical development program have been accepted for presentation at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco from November 13-17, further demonstrating AbbVie’s strong leadership and ongoing commitment to patients with chronic hepatitis C virus (HCV) infection.
Presentations will highlight new data from Phase 3b studies of AbbVie’s FDA-approved VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), taken with or without ribavirin (RBV), for adults with genotype 1 (GT1) chronic HCV infection, counting studies of GT1 patients with chronic kidney disease and genotype 1b (GT1b) patients with compensated cirrhosis. Additionally, new clinical studies will be presented on AbbVie’s HCV pipeline medicines, ABT-493 and ABT-530, focused on investigating pan-genotypic, ribavirin-free, once-daily treatment options that may allow for shorter treatment durations of as little as eight weeks.
“We are happy to present new data from studies of the VIEKIRA PAK regimen in HCV patients, counting those with chronic kidney disease and GT1b compensated cirrhosis,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “These data, in addition to our findings from our investigational compounds, further demonstrate AbbVie’s firm commitment to supporting the care of patients with chronic HCV infection.”
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, counting rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, counting over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women’s health.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
